Clinical Trial Partners Orcosa is actively supporting investigator-initiated trials using the RITe Platform, creating a pathway to partner with CROs and academic medical centers as trial sites. Potential collaborators can access RITe-based CBD formulations, regulatory guidance, and data management support to advance safety and efficacy research.

Non Opioid Pain The ORAVEXX CBD composition delivered through the RITe platform positions Orcosa to address the opioid-free pain management market. Target pain clinics, orthopedic centers, and sports medicine networks seeking opioid-sparing options, with pilots and case studies to demonstrate outcomes and real-world benefits.

Manufacturing Partnerships The U.S. cGMP-compliant manufacturing facility enables scalable production of RITe-enabled products, making Orcosa an attractive partner for biotech and pharma firms pursuing regulated CBD therapies. Opportunities include clinical supply manufacturing and staged commercial-scale production for partner programs.

Strategic Funding With current revenue and ongoing funding, Orcosa can attract strategic investors and grant support by licensing the RITe platform or ORAVEXX to larger biopharma players. This approach could accelerate commercialization, expand market access, and generate iterative revenue streams.

Regulatory Expansion Headquartered in New Jersey with U.S. manufacturing capabilities, Orcosa can leverage investigator-initiated trials to broaden regulatory footprints across the U.S. and potentially global markets for CBD-based analgesics. Collaboration with national health systems and academic networks can help establish data-driven pathways for approval and adoption.